Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › Texas › Dallas
Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa Dallas, TX keessatti
Qorannoo 10 Luukemiya Limfoositiikii Keessummaa f Dallas fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Namoota walitti qabaa jiraSadarkaa 1
- Baylor University Medical Center, Dallas
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Namoota walitti qabaa jiraSadarkaa 1/2
- Baylor Scott & White Health, Dallas
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- UT Southwestern Medical Center, Dallas
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 2
- Texas Oncology - Sammons Cancer Center, Dallas
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Namoota walitti qabaa jiraSadarkaa 3
- University of Texas - Southwestern Medical Center /ID# 266528, Dallas
Study of SGR-1505 in Mature B-Cell Neoplasms
Namoota walitti qabaa jiraSadarkaa 1
- University of Texas Southwestern, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Namoota walitti qabaa jiraSadarkaa 1/2
- UT Southwestern Medical Center, Dallas
Qorannoo Luukemiya Limfoositiikii Keessummaa magaalota biroo keessatti
- Boston, MAQorannoo 31
- Columbus, OHQorannoo 28
- Durham, NCQorannoo 27
- Washington, DCQorannoo 22
- Seattle, WAQorannoo 20
- Rochester, MNQorannoo 18
- New York City, NYQorannoo 18
- Houston, TXQorannoo 17
- Baldwin Park, CAQorannoo 16
- Milwaukee, WIQorannoo 15
- Chicago, ILQorannoo 14
- Cincinnati, OHQorannoo 14
Qorannoo biroo Dallas keessatti
- Saree OljooQorannoo 55
- Kansara Qara'a Non-Small CellQorannoo 52
- Kansara MetastatikiiQorannoo 42
- Cufama OnneeQorannoo 42
- Saree (Gosoota Hunda)Qorannoo 37
- Kansarii ProstateQorannoo 36
- Kansarii ColorectalQorannoo 33
- ObesityQorannoo 30
- Kansarii OvariiQorannoo 28
- Dhibee QaraQorannoo 27
- Dukkana BladderQorannoo 27
- Kansa EndometiriyaaliiQorannoo 24
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.